PD-L1/HDAC6-IN-1 TFA
Based on 1 Customer Validation
PD-L1/HDAC6-IN-1 TFA is an orally active dual inhibitor of PD-L1 and HDAC6, with IC50 values of 26.8 nM and 78 nM, respectively. PD-L1/HDAC6-IN-1 TFA binds to human and murine PD-L1 proteins with high affinity, while it reduces STAT3 phosphorylation and downregulates PD-L1 expression by inhibiting HDAC6, thus blocking the PD-1/PD-L1 interaction. PD-L1/HDAC6-IN-1 TFA exhibits potent anti-tumor activity in a mouse melanoma model. PD-L1/HDAC6-IN-1 is suitable for research on tumor immune regulation related to melanoma.
For research use only. We do not sell to patients.
- Purity: 99.55%
- Formula: C29H34F3N3O5
- Molecular Weight:561.59
-
Storage:
-20°C, sealed storage, away from moisture
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
-
Solvent & Solubility
- Purity & Documentation
- References
-
Help & FAQs
-
Bioactive Compound Library Max
HY-L181
-
Bioactive Compound Library
HY-L001
-
Cell Cycle/DNA Damage Compound Library
HY-L004
-
Epigenetics Compound Library
HY-L005
-
Immunology/Inflammation Compound Library
HY-L007
-
Histone Modification Research Compound Library
HY-L024
-
Anti-Cancer Compound Library
HY-L025
-
Small Molecule Immuno-Oncology Compound Library
HY-L031
-
Anti-Aging Compound Library
HY-L034
-
Reprogramming Compound Library
HY-L039
-
Oxygen Sensing Compound Library
HY-L045
-
Anti-Breast Cancer Compound Library
HY-L074
-
Anti-Lung Cancer Compound Library
HY-L075
-
Anti-Pancreatic Cancer Compound Library
HY-L077
-
Anti-Blood Cancer Compound Library
HY-L079
-
Anti-Liver Cancer Compound Library
HY-L101
-
Anti-Colorectal Cancer Compound Library
HY-L103
-
Protein-protein Interaction Inhibitor Library
HY-L109
-
Osteogenesis Compound Library
HY-L131
-
Membrane Protein-targeted Compound Library
HY-L149
-
Membrane Receptor-targeted Compound Library
HY-L150
-
Highly Selective Inhibitors Library
HY-L158
-
Anti-Hematopathy Compound Library
HY-L171
-
Anti-Ovarian Cancer Compound Library
HY-L173
-
Multi-Target Compound Library
HY-L176
-
MCE Bioactive Compound Library
HY-L001V
-
Anti-Gastric Cancer Compound Library
HY-L184
-
Anti-Brain Cancer Compound Library
HY-L188
-
High-Throughput Bioactive Compound Library
HY-L205
-
High-Efficiency Gene Editing Compound Library
HY-L244
-
Lactylation Compound Library
HY-L249
Biological Activity
|
HDAC6 78 nM (IC50) |
PD-L1/HDAC6-IN-1 (HP29) (0.1-2.0 μM; 12 h) TFA upregulates the level of acetylated α-tubulin in B16-F10 cells and Jurkat cells[1].
PD-L1/HDAC6-IN-1 (0.1-2.0 μM; 24 h) TFA downregulates the expression of p-STAT3 and PD-L1 in B16-F10 cells[1].
PD-L1/HDAC6-IN-1 TFA shows negligible cytotoxicity against B16-F10, HepG2, MCF-7 and Jurkat cells[1].
PD-L1/HDAC6-IN-1 (0.01-10 μM; 48 h) TFA shows negligible cytotoxicity against HepG2 cells and Jurkat T cells, while dose-dependently increasing the mortality of HepG2 cells co-cultured with Jurkat T cells with an IC50 of 3.4 μM[1].
PD-L1/HDAC6-IN-1 TFA dose-dependently activates luciferase activity in PD-1/PD-L1 NFAT reporter assay (EC50 = 3.15 μM)[1].
PD-L1/HDAC6-IN-1 TFA binds to human PD-L1 and murine PD-L1 with KD values of 179 nM and 73 nM in the ITC assay, and 464 nM and 55.3 nM in the SPR assay, respectively[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:B16-F10 cells, Jurkat cells
-
Concentration:0.1, 0.5, 10, 2.0 μM
-
Incubation Time:12 h
-
Result:Upregulated the level of acetylated α-tubulin in B16-F10 cells and Jurkat cells.
-
Cell Line:B16-F10 cells
-
Concentration:0.1, 0.5, 10, 2.0 μM
-
Incubation Time:24 h
-
Result:Downregulated the expression of p-STAT3 and PD-L1 in B16-F10 cells.
-
Cell Line:HepG2 cells, Jurkat T cells
-
Concentration:0.01, 0.03, 0.1, 0.3, 1, 3.3, 10 μM
-
Incubation Time:48 h
-
Result:Showed negligible cytotoxicity against HepG2 cells and Jurkat T cell.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Male C57BL/6 mice (6–8 weeks old) were subcutaneously inoculated with B16-F10 cells (2 × 105 cells per mouse)[1]
-
Dosage:20 mg/kg
-
Administration:intraperitoneal (i.p.) injection once daily for 14 days
-
Result:Significantly inhibited tumor growth with a TGI of 65.5% without obvious body weight loss or systemic toxicity.
Markedly increased tumor-infiltrating CD3⁺CD4⁺ and CD3⁺CD8⁺ T lymphocytes in melanoma tissues.
Significantly downregulated PD-L1 expression and upregulated acetylated α-tubulin levels in tumor tissues.
Chemical Information
-
Appearance Solid
-
Molecular Weight 561.59
-
Formula C29H34F3N3O5
-
Color White to off-white
-
SMILES
CC1=C(C=CC=C1C2=CC=CC=C2)C3=NC(OC)=C(C=C3)CNCCCCCCC(NO)=O.OC(C(F)(F)F)=O
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
-20°C, sealed storage, away from moisture
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
Solvent & Solubility
DMSO : 100 mg/mL (178.07 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (4.45 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (4.45 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL. * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Purity & Documentation
-
Data Sheet (278 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Handling Instructions (2659 KB)
References
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 1.7807 mL | 8.9033 mL | 17.8066 mL | 44.5165 mL |
| 5 mM | 0.3561 mL | 1.7807 mL | 3.5613 mL | 8.9033 mL | |
| 10 mM | 0.1781 mL | 0.8903 mL | 1.7807 mL | 4.4516 mL | |
| 15 mM | 0.1187 mL | 0.5936 mL | 1.1871 mL | 2.9678 mL | |
| 20 mM | 0.0890 mL | 0.4452 mL | 0.8903 mL | 2.2258 mL | |
| 25 mM | 0.0712 mL | 0.3561 mL | 0.7123 mL | 1.7807 mL | |
| 30 mM | 0.0594 mL | 0.2968 mL | 0.5936 mL | 1.4839 mL | |
| 40 mM | 0.0445 mL | 0.2226 mL | 0.4452 mL | 1.1129 mL | |
| 50 mM | 0.0356 mL | 0.1781 mL | 0.3561 mL | 0.8903 mL | |
| 60 mM | 0.0297 mL | 0.1484 mL | 0.2968 mL | 0.7419 mL | |
| 80 mM | 0.0223 mL | 0.1113 mL | 0.2226 mL | 0.5565 mL | |
| 100 mM | 0.0178 mL | 0.0890 mL | 0.1781 mL | 0.4452 mL |
PD-L1/HDAC6-IN-1 TFA Related Classifications
HY-172200A Related Classifications
Powered by Bioz